WMS Partners’s Teva Pharmaceuticals TEVA Stock Holding History

WMS Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-3,718	Closed	-$210K	–	207
2015 Q3	$210K	Sell	3,718 -4,321	-54%	-$280K	0.03%	190
2015 Q2	$475K	Buy	8,039 +132	+2%	+$8.14K	0.06%	176
2015 Q1	$493K	Buy	7,907 +3,214	+68%	+$187K	0.06%	162
2014 Q4	$270K	Buy	4,693 +175	+4%	+$9.75K	0.04%	175
2014 Q3	$243K	Hold	4,518	–	–	0.04%	215
2014 Q2	$237K	Hold	4,518	–	–	0.04%	220
2014 Q1	$239K	Buy	+4,518	New	+$209K	0.04%	215
2013 Q4	–	Sell	-7,553	Closed	-$285K	–	240
2013 Q3	$285K	Buy	7,553 +220	+3%	+$8.58K	0.05%	157
2013 Q2	$288K	Buy	+7,333	New	+$286K	0.05%	176

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

WMS Partners's TEVA Position: Q4 2015 in Review

WMS Partners sold out of Teva Pharmaceuticals (TEVA) in Q4 2015, closing a stake of 3,718 shares — an estimated $210K sold.

WMS Partners first reported a position in TEVA in Q2 2013 and held it in 9 quarters. The position peaked at $493K in Q1 2015. 876 funds tracked by Wall St. Rank hold TEVA as of Q4 2015.

WMS Partners reported no remaining Teva Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
WMS Partners sold 3,718 Teva Pharmaceuticals shares in Q4 2015, an estimated $210K.
WMS Partners first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 9 quarters.
WMS Partners's Teva Pharmaceuticals position peaked at $493K in Q1 2015.
876 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2015.

Based on WMS Partners's 13F filing for Q4 2015, filed 4 Feb 2016.